Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPSCARISBRICK, JuliaHORWITZ, Steven M.PRINCE, H. MilesWHITTAKER, SeanDUVIC, MadeleineKIM, Youn H.QUAGLINO, PietroZINZANI, Pier LuigiBECHTER, OliverERADAT, HerbertPINTER-BROWN, LaurenAKILOV, OlegGESKIN, LarisaSANCHES, JoseORTIZ-ROMERO, PabloLISANO, JulieBROWN, LisaBUNN, VeronicaLITTLE, MeredithDUMMER, Reinhard2020-06-172020-06-172019EUROPEAN JOURNAL OF CANCER, v.119, suppl.1, p.S31-S31, 20190959-8049https://observatorio.fm.usp.br/handle/OPI/36382engrestrictedAccessBrentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA studyconferenceObjectCopyright ELSEVIER SCI LTDOncology1879-0852